Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $74.95 billion. The enterprise value is $59.98 billion.
| Market Cap | 74.95B |
| Enterprise Value | 59.98B |
Important Dates
The last earnings date was Tuesday, February 4, 2025, before market open.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | Feb 20, 2025 |
Share Statistics
REGN has 107.02 million shares outstanding. The number of shares has increased by 1.23% in one year.
| Current Share Class | 105.21M |
| Shares Outstanding | 107.02M |
| Shares Change (YoY) | +1.23% |
| Shares Change (QoQ) | -2.07% |
| Owned by Insiders (%) | 3.61% |
| Owned by Institutions (%) | 89.75% |
| Float | 102.99M |
Valuation Ratios
The trailing PE ratio is 18.27 and the forward PE ratio is 16.25. REGN's PEG ratio is 1.11.
| PE Ratio | 18.27 |
| Forward PE | 16.25 |
| PS Ratio | 5.32 |
| Forward PS | 5.05 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.66 |
| P/FCF Ratio | 20.45 |
| P/OCF Ratio | 16.96 |
| PEG Ratio | 1.11 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.96, with an EV/FCF ratio of 16.37.
| EV / Earnings | 13.59 |
| EV / Sales | 4.22 |
| EV / EBITDA | 12.96 |
| EV / EBIT | 14.47 |
| EV / FCF | 16.37 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.73 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | 0.80 |
| Interest Coverage | 75.09 |
Financial Efficiency
Return on equity (ROE) is 15.95% and return on invested capital (ROIC) is 8.49%.
| Return on Equity (ROE) | 15.95% |
| Return on Assets (ROA) | 7.31% |
| Return on Invested Capital (ROIC) | 8.49% |
| Return on Capital Employed (ROCE) | 12.26% |
| Revenue Per Employee | $940,156 |
| Profits Per Employee | $292,109 |
| Employee Count | 15,106 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.51 |
Taxes
In the past 12 months, REGN has paid $367.30 million in taxes.
| Income Tax | 367.30M |
| Effective Tax Rate | 7.68% |
Stock Price Statistics
The stock price has decreased by -26.04% in the last 52 weeks. The beta is 0.08, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -26.04% |
| 50-Day Moving Average | 705.33 |
| 200-Day Moving Average | 933.23 |
| Relative Strength Index (RSI) | 52.55 |
| Average Volume (20 Days) | 929,249 |
Short Selling Information
The latest short interest is 2.19 million, so 2.04% of the outstanding shares have been sold short.
| Short Interest | 2.19M |
| Short Previous Month | 2.12M |
| Short % of Shares Out | 2.04% |
| Short % of Float | 2.12% |
| Short Ratio (days to cover) | 2.52 |
Income Statement
In the last 12 months, REGN had revenue of $14.20 billion and earned $4.41 billion in profits. Earnings per share was $38.34.
| Revenue | 14.20B |
| Gross Profit | 7.10B |
| Operating Income | 4.15B |
| Pretax Income | 4.59B |
| Net Income | 4.41B |
| EBITDA | 4.63B |
| EBIT | 4.15B |
| Earnings Per Share (EPS) | $38.34 |
Balance Sheet
The company has $9.01 billion in cash and $2.94 billion in debt, giving a net cash position of $14.97 billion or $139.91 per share.
| Cash & Cash Equivalents | 9.01B |
| Total Debt | 2.94B |
| Net Cash | 14.97B |
| Net Cash Per Share | $139.91 |
| Equity (Book Value) | 29.35B |
| Book Value Per Share | 273.57 |
| Working Capital | 14.72B |
Cash Flow
In the last 12 months, operating cash flow was $4.42 billion and capital expenditures -$755.90 million, giving a free cash flow of $3.66 billion.
| Operating Cash Flow | 4.42B |
| Capital Expenditures | -755.90M |
| Free Cash Flow | 3.66B |
| FCF Per Share | $34.24 |
Margins
Gross margin is 49.99%, with operating and profit margins of 29.19% and 31.07%.
| Gross Margin | 49.99% |
| Operating Margin | 29.19% |
| Pretax Margin | 33.66% |
| Profit Margin | 31.07% |
| EBITDA Margin | 32.59% |
| EBIT Margin | 29.19% |
| FCF Margin | 25.80% |
Dividends & Yields
This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 0.13%.
| Dividend Per Share | $0.88 |
| Dividend Yield | 0.13% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 2.30% |
| Buyback Yield | -1.23% |
| Shareholder Yield | -1.11% |
| Earnings Yield | 5.89% |
| FCF Yield | 4.89% |
Analyst Forecast
The average price target for REGN is $996.00, which is 42.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $996.00 |
| Price Target Difference | 42.22% |
| Analyst Consensus | Buy |
| Analyst Count | 26 |
| Revenue Growth Forecast (5Y) | 7.21% |
| EPS Growth Forecast (5Y) | 13.67% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 9.82 and a Piotroski F-Score of 4.
| Altman Z-Score | 9.82 |
| Piotroski F-Score | 4 |